Glutathione S-transferases--biomarkers of cancer risk and chemopreventive response.
The critical role of the glutathione S-transferase (GST) multigene family in cellular protection in combination with the large interindividual variability in the expression of these enzymes has prompted an investigation of their importance in cancer prevention and susceptibility. Previous preclinical and clinical studies from this laboratory have established an association between decreased GST activity and increased risk for colorectal cancer. Based upon the increased incidence of colon malignancies among patients with ulcerative colitis, GST activity has been examined in a mouse model of induced colitis. Significant decreases (50% of controls) in the GST activity of colon tissue were observed during the establishment and progression of colitis. These data suggested that depletion of cellular protection may be an important event in the carcinogenic progression of ulcerative colitis. The ability of the dithiolthione oltipraz to induce GST expression within the murine colon has been demonstrated. Use of chemopreventive regimens to induce phase 2 detoxication enzyme expression represents a promising strategy for the prevention of cancer. Clinical studies revealed that the GST activity of blood lymphocytes from individuals with either a personal or family history of colorectal cancer or a personal history of colon polyps was decreased significantly when compared to that of healthy controls. Phase 1 clinical evaluation of oltipraz has demonstrated its ability to induce GST activity as well as the level of transcripts encoding gamma-glutamylcysteine synthetase (gamma-GCS) and DT-diaphorase in the colon mucosa of individuals at increased risk for colorectal cancer. The observed correlation between the posttreatment response in blood lymphocytes and colon mucosa suggested that blood lymphocytes may be used in future trials as a surrogate biomarker of the responsiveness of colon tissue to chemopreventive regimens.
Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
M L
ML
Clapper
C E
CE
Szarka
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology; D015415:Biomarkers; D001937:Brassica; D003093:Colitis, Ulcerative / Q000150:complications / Q000201:enzymology; D015179:Colorectal Neoplasms / Q000201:enzymology / Q000209:etiology; D004195:Disease Models, Animal; D004790:Enzyme Induction; D015870:Gene Expression; D005982:Glutathione Transferase / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008658:Inactivation, Metabolic; D051379:Mice; D009369:Neoplasms / Q000201:enzymology / Q000209:etiology* / Q000517:prevention & control*; D011719:Pyrazines / Q000494:pharmacology; D012307:Risk Factors; D013871:Thiones; D013876:Thiophenes
D016588:Anticarcinogenic Agents; D015415:Biomarkers; D011719:Pyrazines; D013871:Thiones; D013876:Thiophenes; C026209:oltipraz; D005982:Glutathione Transferase